Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients.

ABSTRACT:

Background

Primary goal of this randomized, double-blind, placebo-controlled crossover study of Renadyl in end-stage renal disease patients was to assess the safety and efficacy of Renadyl measured through improvement in quality of life or reduction in levels of known uremic toxins. Secondary goal was to investigate the effects on several biomarkers of inflammation and oxidative stress.

Methods

Two 2-month treatment periods separated by 2-month washout and crossover, with physical examinations, venous blood testing, and quality of life questionnaires completed at each visit. Data were analyzed with SAS V9.2.

Results

22 subjects (79%) completed the study. Observed trends were as follows (none reaching statistical significance): decline in WBC count (-0.51 × 10(9)/L, P

SUBMITTER: Natarajan R 

PROVIDER: S-EPMC4132402 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature